The nanoinhibitor showed significant tumor inhibition in HIPEC therapy by preferring to bind HSP90 in tumor cells rather than normal cells because of abundancy and high affinity in tumor cells [17]. This evidence concerns the gene HSP90AA1 and neoplasm.